Marc Van den Eynde
A5016173075- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Surgical Treatments
- Colorectal and Anal Carcinomas
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Radiomics and Machine Learning in Medical Imaging
- Immunotherapy and Immune Responses
- Intraperitoneal and Appendiceal Malignancies
- Pancreatic and Hepatic Oncology Research
- Immune Cell Function and Interaction
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Medical Imaging Techniques and Applications
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Radiopharmaceutical Chemistry and Applications
- CAR-T cell therapy research
- Neuroendocrine Tumor Research Advances
- Ferroptosis and cancer prognosis
- Advanced Radiotherapy Techniques
- HER2/EGFR in Cancer Research
- Cancer Research and Treatments
- Esophageal Cancer Research and Treatment
Cliniques Universitaires Saint-Luc
2016-2025
UCLouvain
2015-2024
Sorbonne Paris Cité
2017-2018
Centre de Recherche des Cordeliers
2017-2018
Laboratoire d’immunologie intégrative du cancer
2017-2018
Université Paris Cité
2017-2018
Inserm
2017-2018
Sorbonne Université
2017-2018
Celyad (Belgium)
2018
Délégation Paris 5
2017
This study assesses how the metastatic immune landscape is impacting response to treatment and outcome of colorectal cancer (CRC) patients. Complete curative resection metastases (n = 441) was performed for two patient cohorts 153). Immune densities were quantified in center invasive margin all metastases. Immunoscore T B cell (TB) score analyzed relation radiological pathological responses patient’s disease-free (DFS) overall survival (OS) using multivariable Cox proportional hazards...
The purpose of this study was to evaluate the prognostic value Immunoscore in patients with stage III colon cancer (CC) and analyze its association effect chemotherapy on time recurrence (TTR).
The lack of multi-omics cancer datasets with extensive follow-up information hinders the identification accurate biomarkers clinical outcome. In this cohort study, we performed comprehensive genomic analyses on fresh-frozen samples from 348 patients affected by primary colon cancer, encompassing RNA, whole-exome, deep T cell receptor and 16S bacterial rRNA gene sequencing tumor matched healthy tissue, complemented whole-genome for further microbiome characterization. A type 1 helper cell,...
3501 Background: T-DXd (6.4 mg/kg, every 3 weeks [Q3W]) demonstrated antitumor activity in pts with HER2+ mCRC DESTINY-CRC01 (Siena et al. Lancet Oncol. 2021). We present primary results of DESTINY-CRC02 (NCT04744831), which assessed the efficacy and safety (5.4 6.4 mg/kg) mCRC. Methods: This was a multicenter phase 2 study. Eligible had centrally confirmed (immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+) Pts RAS wild-type (wt) mutant (m) were eligible. received prior...
Abstract Purpose: No biomarker to personalize treatment in locally advanced rectal cancer (LARC) is currently available. We assessed LARC whether a diagnostic biopsy-adapted immunoscore (ISB) could predict response neoadjuvant (nT) and better define patients eligible an organ preservation strategy (“Watch-and-Wait”). Experimental Design: Biopsies from two independent cohorts (n1 = 131, n2 118) of with treated nT followed by radical surgery were immunostained for CD3+ CD8+ T cells quantified...
Background New and fully validated tests need to be brought into clinical practice improve the estimation of recurrence risk in patients with colon cancer. The aim this study was assess analytical performances Immunoscore (IS) show its contribution prognosis prediction. Methods Immunohistochemical staining CD3+ CD8+ T cells on adjacent sections cancer tissues were quantified core tumor invasive margin dedicated IS modules integrated digital pathology software. Staining intensity across...
Background: The prognostic value of Immunoscore was evaluated in Stage II/III colon cancer (CC) patients, but it remains unclear I/II, and early-stage subgroups at risk. An international Society for Immunotherapy Cancer (SITC) study the pre-defined consensus tumors from 1885 AJCC/UICC-TNM I/II CC patients Canada/USA (Cohort 1) Europe/Asia 2). METHODS: Digital-pathology is used to quantify densities CD3+ CD8+ T-lymphocyte center tumor (CT) invasive margin (IM). time recurrence (TTR) primary...
Selective internal radiation therapy (SIRT) has shown good results in unresectable liver metastases from neuroendocrine neoplasms (NELM) with a high disease control rate (DCR) reported. The aims of the study is to assess retrospectively efficacy and safety 10y SIRT for NELM. Primary endpoint was objective response (ORR) DCR by RECIST 1.1 at 2, 4 12 months (m). Secondary endpoints were overall survival (OS), progressionfree (liver-PFS), clinical (NEN-related symptoms improvement) safety. 50...